Information only, not medical advice. Talk to your doctor or pharmacist.
Condition
Cardiovascular
6 approvals (7 source records) from January 1, 2025 through . Data pulled .
July 2026
REDEMPLO
PLOZASIRAN (PLOZASIRAN SODIUM) 25 MG
Company: ARROWHEAD PHARMACEUTICALS, INC.
Original market date:
Data pulled:
Condition mapped from Health Canada ATC C10AX OTHER LIPID MODIFYING AGENTS.
- DIN: 02564327
- Drug code: 106703
- DPD status: Marketed
- Therapeutic class: C10AX OTHER LIPID MODIFYING AGENTS
VANRAFIA
ATRASENTAN (ATRASENTAN HYDROCHLORIDE) 0.75 MG
Company: NOVARTIS PHARMACEUTICALS CANADA INC
Authorization date:
Data pulled:
Condition mapped from Health Canada ATC C09XX OTHER AGENTS ACTING ON THE RENIN -ANGIOTENSIN SYSTEM.
- DIN: 02569590
- Drug code: 107182
- DPD status: Approved
- Therapeutic class: C09XX OTHER AGENTS ACTING ON THE RENIN -ANGIOTENSIN SYSTEM
February 2026
NILEMDO
BEMPEDOIC ACID 180 MG
Company: HLS THERAPEUTICS INC
Original market date:
Data pulled:
Condition mapped from Health Canada ATC C10AX15 BEMPEDOIC ACID.
- DIN: 02562782
- Drug code: 106563
- DPD status: Marketed
- Therapeutic class: C10AX15 BEMPEDOIC ACID
TRYNGOLZA
OLEZARSEN (OLEZARSEN SODIUM) 80 MG
Company: CELYSTRA PHARMA INC.
Original market date:
Data pulled:
Condition mapped from Health Canada ATC C10AX OTHER LIPID MODIFYING AGENTS.
- DIN: 02563886
- Drug code: 106662
- DPD status: Marketed
- Therapeutic class: C10AX OTHER LIPID MODIFYING AGENTS
December 2025
JERAYGO
APROCITENTAN 25 MG
Company: IDORSIA PHARMACEUTICALS LTD
Authorization date:
Data pulled:
Condition mapped from Health Canada ATC C02KN01 APROCITENTAN.
- DIN: 02563991
- Drug code: 106673
- DPD status: Approved
- Therapeutic class: C02KN01 APROCITENTAN
August 2025
NB-AMLODIPINE
AMLODIPINE BESYLATE 5 MG; AMLODIPINE BESYLATE 10 MG
Company: NB PHARMA INC.
Original market date:
Data pulled:
Condition mapped from Health Canada ATC C08CA01 AMLODIPINE.
- DIN: 02556715, 02556723
- Drug code: 106011, 106012
- DPD status: Marketed
- Therapeutic class: C08CA01 AMLODIPINE